These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1579 related articles for article (PubMed ID: 12819520)
1. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD; AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520 [TBL] [Abstract][Full Text] [Related]
2. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients. Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696 [TBL] [Abstract][Full Text] [Related]
3. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. Kwong GP; Ghani AC; Rode RA; Bartley LM; Cowling BJ; da Silva B; Donnelly CA; van Sighem AI; Cameron DW; Danner SA; de Wolf F; Anderson RM AIDS; 2006 Oct; 20(15):1941-50. PubMed ID: 16988515 [TBL] [Abstract][Full Text] [Related]
5. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752 [TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884 [TBL] [Abstract][Full Text] [Related]
7. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765 [TBL] [Abstract][Full Text] [Related]
8. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Patel N; Abdelsayed S; Veve M; Miller CD Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. Rimland D; Guest JL; Hernández I; Del Rio C; Le NA; Brown WV HIV Med; 2005 Sep; 6(5):326-33. PubMed ID: 16156880 [TBL] [Abstract][Full Text] [Related]
10. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408 [TBL] [Abstract][Full Text] [Related]
11. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110 [TBL] [Abstract][Full Text] [Related]
12. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F; HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343 [TBL] [Abstract][Full Text] [Related]
14. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262 [TBL] [Abstract][Full Text] [Related]
15. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D; AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330 [TBL] [Abstract][Full Text] [Related]
16. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251 [TBL] [Abstract][Full Text] [Related]
17. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037 [TBL] [Abstract][Full Text] [Related]
18. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR; Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328 [TBL] [Abstract][Full Text] [Related]
19. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351 [TBL] [Abstract][Full Text] [Related]
20. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings. Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]